3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(5-bromo-1H-indol-3-yl)pyrrole-2,5-dione | 345265-19-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(5-bromo-1H-indol-3-yl)pyrrole-2,5-dione
• 英文别名: 3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(5-bromo-1H-indol-3-yl)-pyrrole-2,5-dione；3-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-4-(5-bromo-1H-indol-3-yl)pyrrole-2,5-dione
• CAS: 345265-19-2
• 化学式: C₂₃H₁₆BrN₃O₂
• 分子量: 446.303
• InChiKey: LLOCLQTXVAQSBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  66.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(5-bromo-1H-indol-3-yl)pyrrole-2,5-dione 以 甲醇 为溶剂， 以to yield (±)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(5-bromo-1H-indol-3-yl)pyrrolidine-2,5-dione的产率得到(+/-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4-(5-bromo-1H-indol-3-yl)pyrrolidine-2,5-dione
  参考文献：
  名称：

  Compositions and Methods for Treatment of Cancer

  摘要：

  本发明涉及吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物及其制备方法。本发明还涉及包含吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物的制药组合物。本发明提供了通过向需要治疗细胞增殖性疾病，例如癌症的患者施用本发明的吡咯喹啉基吡咯-2,5-二酮化合物或吡咯喹啉基吡咯烷-2,5-二酮化合物的治疗有效量的方法。

  公开号：

  US20100221251A1
• 作为产物：
  描述：

  2-(5,6-二氢-4H-吡咯并[3,2,1-IJ]喹啉-1-基)-2-氧代乙酸甲酯 在 盐酸 、 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 生成 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(5-bromo-1H-indol-3-yl)pyrrole-2,5-dione
  参考文献：
  名称：

  1,7-Annulated indolocarbazoles as cyclin-dependent kinase inhibitors

  摘要：

  The synthesis and kinase inhibitory activity of a series of novel 1,7-annulated indolocarbazoles 6 and 16 is described. These compounds exhibited potent inhibitory activity against cyclin-dependent kinase 4 and good antiproliferative activity in a human colon carcinoma cell line. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.105

文献信息

• Agents and methods for the treatment of proliferative diseases
  申请人：——

  公开号：US20030229026A1

  公开（公告）日：2003-12-11

  The present invention provides selective kinase inhibitors of formula (I). 1

  这项发明提供了式（I）的选择性激酶抑制剂。
• COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
  申请人：ArQule, Inc.

  公开号：US20150328208A1

  公开（公告）日：2015-11-19

  The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.

  本发明提供了治疗细胞增殖紊乱（如癌症）的方法，通过向需要的受试者投予一种吡啶喹啉基吡咯-2,5-二酮化合物或吡啶喹啉基吡咯啉-2,5-二酮化合物的治疗有效量，与第二种抗增殖剂的治疗有效量结合使用。
• Compositions and Methods for Treatment of Cancer
  申请人：Li Chiang J.

  公开号：US20100221251A1

  公开（公告）日：2010-09-02

  The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.

  本发明涉及吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物及其制备方法。本发明还涉及包含吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物的制药组合物。本发明提供了通过向需要治疗细胞增殖性疾病，例如癌症的患者施用本发明的吡咯喹啉基吡咯-2,5-二酮化合物或吡咯喹啉基吡咯烷-2,5-二酮化合物的治疗有效量的方法。
• Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer
  申请人：ArQule, Inc.

  公开号：EP2289892A1

  公开（公告）日：2011-03-02

  The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.

  本发明涉及吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物，以及这些化合物的制备方法。本发明还涉及包含吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物的药物组合物。本发明提供了治疗细胞增殖性疾病（如癌症）的方法，即向有需要的受试者施用治疗有效量的本发明的吡咯喹啉基吡咯-2,5-二酮化合物或吡咯喹啉基吡咯烷-2,5-二酮化合物。
• WO2006/86484
  申请人：——

  公开号：——

  公开（公告）日：——